Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Core Viewpoint - Syndax Pharmaceuticals will report its first quarter 2025 financial results and provide a business update on May 5, 2025 [1] Financial Results Announcement - The management will host a conference call and live audio webcast at 4:30 p.m. ET on May 5, 2025, to discuss financial results and business updates [2] - Access to the live audio webcast and slides will be available on the Company's website, with a replay accessible approximately 24 hours after the call for 90 days [2] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing an innovative pipeline of cancer therapies [3] - Key products in the pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3] - The company is committed to advancing cancer care through various clinical trials [3]